Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Post by stefchillon Jun 01, 2020 11:10am

90 Views

Post# 31096363

lvl 2 look very nice

Let's get some info on the podcast on SK and USA IND. I don't think they would have submitted to the US unless SK trials were going well! we just need patience and people stop selling into the bids and this could fly.

cheers

Level 2 Quote

Orders/Shares	Bid Price	Ask Price	Shares/Orders
7 / 35,500	0.33	0.34	27,000 / 4
2 / 3,000	0.325	0.345	33,000 / 5
14 / 120,500	0.32	0.35	19,000 / 4
4 / 8,500	0.315	0.355	20,000 / 2
5 / 11,500	0.31	0.36	28,500 / 4
7 / 38,000	0.305	0.365	1,500 / 1
9 / 27,000	0.30	0.37	28,500 / 3
3 / 11,000	0.295	0.38	8,000 / 3
11 / 58,000	0.29	0.39	49,000 / 2